An optimized reference tissue method for quantification of tau protein depositions in diverse neurodegenerative disorders by PET with

Humans Alzheimer Disease / diagnostic imaging Frontotemporal Dementia / diagnostic imaging Positron-Emission Tomography / standards Supranuclear Palsy, Progressive / diagnostic imaging tau Proteins / analysis Tauopathies / diagnostic imaging Cerebellum / diagnostic imaging Reference Standards
Alzheimer's disease Frontotemporal lobar degeneration Progressive supranuclear palsy Reference tissues Tau PET

Journal

NeuroImage
ISSN: 1095-9572
Titre abrégé: Neuroimage
Pays: United States
ID NLM: 9215515

Informations de publication

Date de publication:
01 12 2022
Historique:
received: 14 02 2022
revised: 15 10 2022
accepted: 21 11 2022
pubmed: 26 11 2022
medline: 15 12 2022
entrez: 25 11 2022
Statut: ppublish

Résumé

Positron emission tomography (PET) with

Identifiants

DOI: 10.1016/j.neuroimage.2022.119763 PMID: 36427751
pubmed: 36427751
pii: S1053-8119(22)00884-9
doi: 10.1016/j.neuroimage.2022.119763
pii:
doi:

Substances chimiques

tau Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

119763

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Hitoshi Shimada, Ming-Rong Zhang, and Makoto Higuchi hold patents on compounds related to the present report (JP 5422782/EP 12 884 742.3/CA2894994/HK1208672).

Auteurs

Kenji Tagai (K)

Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan; Department of Psychiatry, The Jikei University of Medicine, Tokyo 105-8461, Japan. Electronic address: tagai.kenji@qst.go.jp.

Yoko Ikoma (Y)

Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan.

Hironobu Endo (H)

Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan.

Oiendrila Bhowmik Debnath (OB)

Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan.

Chie Seki (C)

Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan.

Kiwamu Matsuoka (K)

Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan.

Hideki Matsumoto (H)

Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan.

Masaki Oya (M)

Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan.

Kosei Hirata (K)

Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan.

Hitoshi Shinotoh (H)

Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan.

Keisuke Takahata (K)

Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan; Department of Psychiatry, Keio University School of Medicine, Tokyo 160-0016, Japan.

Shin Kurose (S)

Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan; Department of Psychiatry, Keio University School of Medicine, Tokyo 160-0016, Japan.

Yasunori Sano (Y)

Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan; Department of Psychiatry, Keio University School of Medicine, Tokyo 160-0016, Japan.

Maiko Ono (M)

Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan.

Hitoshi Shimada (H)

Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan; Department of Functional Neurology & Neurosurgery, Center for Integrated Human Brain Science, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.

Kazunori Kawamura (K)

Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan.

Ming-Rong Zhang (MR)

Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan.

Yuhei Takado (Y)

Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan. Electronic address: takado.yuhei@qst.go.jp.

Makoto Higuchi (M)

Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Institute for Quantum Medical Science, Chiba 263-8555, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › An optimized reference tissue method for...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › An optimized reference tissue method for...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Dégénérescence lobaire frontotemporale › Démence frontotemporale › An optimized reference tissue method for...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › An optimized reference tissue method for...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations neurologiques › Paralysie › Ophtalmoplégie › Paralysie supranucléaire progressive › An optimized reference tissue method for...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › Protéines associées aux microtubules › Protéines tau › An optimized reference tissue method for...
questionsmedicales.fr › Maladies du système nerveux › Maladies neurodégénératives › Tauopathies › An optimized reference tissue method for...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Tronc cérébral › Rhombencéphale › Métencéphale › Cervelet › An optimized reference tissue method for...
questionsmedicales.fr › Techniques d'investigation › Poids et mesures › Normes de référence › An optimized reference tissue method for...